Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 16/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4907377 | 0.91 | CTSK (0.60) | CTSKPOLBCTSLCTSBCTSS | |
| SCHEMBL4896876 | 0.86 | CTSK (0.57) | CTSKPOLBCTSLCTSBCTSS | |
| SCHEMBL4899328 | 0.86 | CTSK (0.69) | CTSKCTSLCTSBCTSS | |
| SCHEMBL4895966 | 0.84 | CTSK (0.61) | CTSKPOLBCTSLCTSBCTSS | |
| SCHEMBL4906745 | 0.84 | CTSK (0.57) | CTSKPOLBCTSLCTSBCTSS | |
| SCHEMBL4898947 | 0.84 | CTSK (0.64) | CTSKRAB9APOLBTP53SMN1; SMN2 | |
| SCHEMBL14260287 | 0.82 | CTSK (0.76) | CTSKCTSLCTSBCTSS | |
| SCHEMBL4904858 | 0.80 | CTSK (0.58) | CTSKPOLBCTSLCTSBCTSS | |
| SCHEMBL4905551 | 0.79 | CTSK (0.60) | CTSKRAB9APOLBSMN1; SMN2CTSL | |
| SCHEMBL4896822 | 0.79 | CTSK (0.53) | CTSKMEN1KMT2APOLBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058333-A1 | CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS CATHEPSIN K INHIBITORS | CATALANO JOHN G | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058333-A1 | CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS CATHEPSIN K INHIBITORS | CTSK, CTSS, CTSE | CTSK 1/4885MEN1 4424/4885ALDH1A1 4266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.